Prof. Changhoon Yoo
Associate Professor,
Department of Oncology, Asan Medical Center,
University of Ulsan College of Medicine, Seoul, Korea
Abstract
In 2020, nearly half of new pancreatic cancer cases worldwide were reported in Asia. In Korea, standards of care for metastatic pancreatic cancer (mPaCa) are similar to Europe with some noticeable differences in 2L treatment option. In this webinar, Prof Changhoon Yoo from the Asan Medical Center (Seoul) will present mPaCa treatment trend in Korea, focusing on first, second and third line treatment options. Clinical cases will be presented and a special focus will be on liposomal irinotecan usage at the second line setting.
